
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5447330/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis and Rheumatism, 2012, 64, 2677-2686.	6.7	3,838
2	2013 Classification Criteria for Systemic Sclerosis: An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative. Arthritis and Rheumatism, 2013, 65, 2737-2747.	6.7	2,359
3	2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative. Annals of the Rheumatic Diseases, 2013, 72, 1747-1755.	0.9	1,705
4	Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. Annals of the Rheumatic Diseases, 2014, 73, 958-967.	0.9	558
5	Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort. Annals of the Rheumatic Diseases, 2015, 74, 1706-1713.	0.9	391
6	The frequency and outcome of lupus nephritis: results from an international inception cohort study. Rheumatology, 2016, 55, 252-262.	1.9	370
7	Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in behçet's disease: An openâ€label trial. Arthritis and Rheumatism, 2005, 52, 2478-2484.	6.7	289
8	European multicentre study to define disease activity criteria for systemic sclerosis. II. Identification of disease activity variables and development of preliminary activity indexes. Annals of the Rheumatic Diseases, 2001, 60, 592-598.	0.9	271
9	A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS). Annals of the Rheumatic Diseases, 2017, 76, 554-561.	0.9	268
10	Antiphospholipid antibodies and antiphospholipid syndrome in patients presenting with immune thrombocytopenic purpura: a prospective cohort study. Blood, 2001, 98, 1760-1764.	1.4	203
11	Accuracy of anti–ribosomal P protein antibody testing for the diagnosis of neuropsychiatric systemic lupus erythematosus: An international meta-analysis. Arthritis and Rheumatism, 2006, 54, 312-324.	6.7	201
12	Familial aggregation of Behcet's disease in Turkey. Annals of the Rheumatic Diseases, 2000, 59, 622-625.	0.9	164
13	Seizure disorders in systemic lupus erythematosus results from an international, prospective, inception cohort study. Annals of the Rheumatic Diseases, 2012, 71, 1502-1509.	0.9	143
14	Identification of Multiple Genetic Susceptibility Loci in Takayasu Arteritis. American Journal of Human Genetics, 2013, 93, 298-305.	6.2	143
15	Predictors of lymphoma development in primary Sjögren's syndrome. Seminars in Arthritis and Rheumatism, 1998, 28, 80-87.	3.4	124
16	Nailfold Videocapillaroscopic Features and Other Clinical Risk Factors for Digital Ulcers in Systemic Sclerosis: A Multicenter, Prospective Cohort Study. Arthritis and Rheumatology, 2016, 68, 2527-2539.	5.6	122
17	Clinical prediction of 5-year survival in systemic sclerosis: validation of a simple prognostic model in EUSTAR centres. Annals of the Rheumatic Diseases, 2011, 70, 1788-1792.	0.9	107
18	Treatment outcome in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study (ESOS). Annals of the Rheumatic Diseases, 2017, 76, 1207-1218.	0.9	107

#	Article	IF	CITATIONS
19	Anti-C1q antibodies in systemic lupus erythematosus. Lupus, 2015, 24, 42-49.	1.6	106
20	Comparative study of the skin pathergy test with blunt and sharp needles in Behcet's disease: confirmed specificity but decreased sensitivity with sharp needles Annals of the Rheumatic Diseases, 1993, 52, 823-825.	0.9	100
21	Mood Disorders in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. Arthritis and Rheumatology, 2015, 67, 1837-1847.	5.6	98
22	Assessment of disease activity and progression in Takayasu's arteritis with Disease Extent Index-Takayasu. Rheumatology, 2010, 49, 1889-1893.	1.9	97
23	2021 DORIS definition of remission in SLE: final recommendations from an international task force. Lupus Science and Medicine, 2021, 8, e000538.	2.7	97
24	Tuberculosis in Turkish patients with systemic lupus erythematosus: increased frequency of extrapulmonary localization. Lupus, 2004, 13, 274-278.	1.6	90
25	Treatment Algorithms in Systemic Lupus Erythematosus. Arthritis Care and Research, 2015, 67, 1237-1245.	3.4	88
26	An assessment of disease flare in patients with systemic lupus erythematosus: a comparison of BILAG 2004 and the flare version of SELENA. Annals of the Rheumatic Diseases, 2011, 70, 54-59.	0.9	86
27	Headache in Systemic Lupus Erythematosus: Results From a Prospective, International Inception Cohort Study. Arthritis and Rheumatism, 2013, 65, 2887-2897.	6.7	84
28	European multicentre study to define disease activity criteria for systemic sclerosis. I. Clinical and epidemiological features of 290 patients from 19 centres. Annals of the Rheumatic Diseases, 2001, 60, 585-591.	0.9	83
29	Identification of Susceptibility Loci in <i>IL6</i> , <i>RPS9</i> / <i>LILRB3</i> , and an Intergenic Locus on Chromosome 21q22 in Takayasu Arteritis in a Genomeâ€Wide Association Study. Arthritis and Rheumatology, 2015, 67, 1361-1368.	5.6	79
30	Clinical associations of the metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort. Annals of the Rheumatic Diseases, 2013, 72, 1308-1314.	0.9	78
31	Anti-CCP antibodies in rheumatoid arthritis and psoriatic arthritis. Clinical Rheumatology, 2007, 26, 17-23.	2.2	76
32	Cluster Analysis of Autoantibodies in 852 Patients with Systemic Lupus Erythematosus from a Single Center. Journal of Rheumatology, 2014, 41, 1304-1310.	2.0	75
33	Phenotypes Determined by Cluster Analysis and Their Survival in the Prospective European Scleroderma Trials and Research Cohort of Patients With Systemic Sclerosis. Arthritis and Rheumatology, 2019, 71, 1553-1570.	5.6	75
34	Impact of early disease factors on metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort. Annals of the Rheumatic Diseases, 2015, 74, 1530-1536.	0.9	70
35	Antinuclear Antibody–Negative Systemic Lupus Erythematosus in an International Inception Cohort. Arthritis Care and Research, 2019, 71, 893-902.	3.4	70
36	Risk factors for avascular bone necrosis in patients with systemic lupus erythematosus. Rheumatology International, 2012, 32, 177-182.	3.0	68

#	Article	IF	CITATIONS
37	A weak association of HLA-B*2702 with Behçet's disease. Genes and Immunity, 2002, 3, 368-372.	4.1	61
38	The Significance and Management of Thrombocytopenia in Antiphospholipid Syndrome. Current Rheumatology Reports, 2015, 17, 14.	4.7	61
39	Takayasu's arteritis is associated with HLA-B*52, but not with HLA-B*51, in Turkey. Arthritis Research and Therapy, 2012, 14, R27.	3.5	60
40	Development of a New International Antiphospholipid Syndrome Classification Criteria Phase I/II Report: Generation and Reduction of Candidate Criteria. Arthritis Care and Research, 2021, 73, 1490-1501.	3.4	60
41	Serologic response to Epstein-Barr virus antigens in patients with systemic lupus erythematosus: a controlled study. Rheumatology International, 2012, 32, 79-83.	3.0	58
42	Cerebrovascular Events in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. Arthritis Care and Research, 2018, 70, 1478-1487.	3.4	55
43	Psychosis in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. Arthritis and Rheumatology, 2019, 71, 281-289.	5.6	55
44	Disability, fatigue, pain and their associates in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study. Rheumatology, 2018, 57, 370-381.	1.9	53
45	The prevalence and determinants of anti-DFS70 autoantibodies in an international inception cohort of systemic lupus erythematosus patients. Lupus, 2017, 26, 1051-1059.	1.6	52
46	Assessment of Cardiac Structure and Left Atrial Appendage Functions in Primary Antiphospholipid Syndrome. Stroke, 2005, 36, 592-596.	2.0	51
47	Off-label use of rituximab for systemic lupus erythematosus in Europe. Lupus Science and Medicine, 2016, 3, e000163.	2.7	51
48	Low frequency of HLA-B27 in ankylosing spondylitis patients from Turkey. Joint Bone Spine, 2008, 75, 299-302.	1.6	50
49	Pulmonary hypertension in systemic lupus erythematosus: relationship with antiphospholipid antibodies and severe disease outcome. Rheumatology International, 2011, 31, 183-189.	3.0	50
50	Patterns and predictors of skin score change in early diffuse systemic sclerosis from the European Scleroderma Observational Study. Annals of the Rheumatic Diseases, 2018, 77, 563-570.	0.9	50
51	Items for developing revised classification criteria in systemic sclerosis: Results of a consensus exercise. Arthritis Care and Research, 2012, 64, 351-357.	3.4	49
52	Interleukin (IL)–12, IL-2, and IL-6 Gene Polymorphisms in Takayasu's Arteritis from Turkey. Human Immunology, 2006, 67, 735-740.	2.4	47
53	Metabolic syndrome is not only a risk factor for cardiovascular diseases in systemic lupus erythematosus but is also associated with cumulative organ damage: a cross-sectional analysis of 311 patients. Lupus, 2016, 25, 177-184.	1.6	47
54	Outcome measurements in scleroderma: results from a delphi exercise. Journal of Rheumatology, 2007, 34, 501-9.	2.0	45

#	Article	IF	CITATIONS
55	Flares after hydroxychloroquine reduction or discontinuation: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort. Annals of the Rheumatic Diseases, 2022, 81, 370-378.	0.9	42
56	A comparison of clinical findings of familial Mediterranean fever patients with and without amyloidosis. Rheumatology International, 2005, 25, 442-446.	3.0	41
57	Comparison of Disease Characteristics, Organ Damage, and Survival in Patients with Juvenile-onset and Adult-onset Systemic Lupus Erythematosus in a Combined Cohort from 2 Tertiary Centers in Turkey. Journal of Rheumatology, 2017, 44, 619-625.	2.0	41
58	A Longitudinal Analysis of Outcomes of Lupus Nephritis in an International Inception Cohort Using a Multistate Model Approach. Arthritis and Rheumatology, 2016, 68, 1932-1944.	5.6	40
59	Neuropsychiatric events in systemic lupus erythematosus: a longitudinal analysis of outcomes in an international inception cohort using a multistate model approach. Annals of the Rheumatic Diseases, 2020, 79, 356-362.	0.9	40
60	Peripheral Nervous System Disease in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. Arthritis and Rheumatology, 2020, 72, 67-77.	5.6	39
61	Impaired endothelium-dependent flow-mediated dilation in Behçet's disease: more prominent endothelial dysfunction in patients with vascular involvement. International Journal of Clinical Practice, 2005, 59, 777-781.	1.7	38
62	Anti-CCP and antikeratin antibodies in rheumatoid arthritis, primary Sjögren's syndrome, and Wegener's granulomatosis. Clinical Rheumatology, 2005, 24, 673-676.	2.2	38
63	Glucocorticoid use and factors associated with variability in this use in the Systemic Lupus International Collaborating Clinics Inception Cohort. Rheumatology, 2018, 57, 677-687.	1.9	37
64	Primary antiphospholipid syndrome associated with mesenteric inflammatory veno-occlusive disease. Clinical Rheumatology, 1996, 15, 207-210.	2.2	34
65	Construction of a Frailty Index as a Novel Health Measure in Systemic Lupus Erythematosus. Journal of Rheumatology, 2020, 47, 72-81.	2.0	34
66	Predictors of Damage and Survival in Patients with Wegener's Granulomatosis: Analysis of 50 Patients. Journal of Rheumatology, 2010, 37, 374-378.	2.0	31
67	Impact of glucocorticoids on the incidence of lupus-related major organ damage: a systematic literature review and meta-regression analysis of longitudinal observational studies. Lupus Science and Medicine, 2021, 8, e000590.	2.7	31
68	Impaired brachial endothelial function in patients with primary anti-phospholipid syndrome. International Journal of Clinical Practice, 2004, 58, 1003-1007.	1.7	30
69	Experience with monthly, high-dose, intravenous immunoglobulin therapy in patients with different connective tissue diseases. Rheumatology International, 2005, 25, 211-214.	3.0	28
70	Safety of high-dose intravenous immunoglobulin in systemic autoimmune diseases. Clinical Rheumatology, 2007, 26, 1913-1915.	2.2	27
71	Soluble urokinase plasminogen activator receptor (suPAR) levels predict damage accrual in patients with recent-onset systemic lupus erythematosus. Journal of Autoimmunity, 2020, 106, 102340.	6.5	27
72	Study of Flare Assessment in Systemic Lupus Erythematosus Based on Paper Patients. Arthritis Care and Research, 2018, 70, 98-103.	3.4	26

#	Article	IF	CITATIONS
73	Prediction of Damage Accrual in Systemic Lupus Erythematosus Using the Systemic Lupus International Collaborating Clinics Frailty Index. Arthritis and Rheumatology, 2020, 72, 658-666.	5.6	26
74	Identification of susceptibility loci for Takayasu arteritis through a large multi-ancestral genome-wide association study. American Journal of Human Genetics, 2021, 108, 84-99.	6.2	26
75	Thrombotic risk in patients submitted to splenectomy for systemic lupus erythematosus and antiphospholipid antibody syndrome-related thrombocytopenia. European Journal of Internal Medicine, 2004, 15, 162-167.	2.2	25
76	Evaluating the Properties of a Frailty Index and Its Association With Mortality Risk Among Patients With Systemic Lupus Erythematosus. Arthritis and Rheumatology, 2019, 71, 1297-1307.	5.6	25
77	Economic Evaluation of Damage Accrual in an International Systemic Lupus Erythematosus Inception Cohort Using a Multistate Model Approach. Arthritis Care and Research, 2020, 72, 1800-1808.	3.4	23
78	The prevalence and clinical significance of inherited thrombophilic risk factors in patients with antiphospholipid syndrome. Journal of Thrombosis and Thrombolysis, 2010, 29, 303-309.	2.1	22
79	Comparison of the 2019 European Alliance of Associations for Rheumatology/American College of Rheumatology Systemic Lupus Erythematosus Classification Criteria With Two Sets of Earlier Systemic Lupus Erythematosus Classification Criteria. Arthritis Care and Research, 2021, 73, 1231-1235.	3.4	22
80	P-selectin glycoprotein ligand-1 VNTR polymorphisms and risk of thrombosis in the antiphospholipid syndrome. Annals of the Rheumatic Diseases, 2007, 66, 1378-1380.	0.9	21
81	Economic Evaluation of Lupus Nephritis in the Systemic Lupus International Collaborating Clinics Inception Cohort Using a Multistate Model Approach. Arthritis Care and Research, 2018, 70, 1294-1302.	3.4	21
82	Eosinophilia and hyperimmunoglobulinemia E as the presenting manifestations of Wegener?s granulomatosis. Clinical Rheumatology, 2003, 22, 333-335.	2.2	19
83	Assessment of Patients with Takayasu Arteritis in Routine Practice with Indian Takayasu Clinical Activity Score. Journal of Rheumatology, 2015, 42, 1443-1447.	2.0	19
84	Monogenic lupus due to spondyloenchondrodysplasia with spastic paraparesis and intracranial calcification: case-based review. Rheumatology International, 2020, 40, 1903-1910.	3.0	19
85	Multicentric reticulohistiocytosis: Rheumatology perspective. Best Practice and Research in Clinical Rheumatology, 2016, 30, 250-260.	3.3	18
86	Antibodies reactive with HIV-1 antigens in systemic lupus erythematosus. Lupus, 1996, 5, 120-122.	1.6	17
87	Accrual of Atherosclerotic Vascular Events in a Multicenter Inception Systemic Lupus Erythematosus Cohort. Arthritis and Rheumatology, 2020, 72, 1734-1740.	5.6	17
88	Physician Global Assessment International Standardisation COnsensus in Systemic Lupus Erythematosus: the PISCOS study. Lancet Rheumatology, The, 2022, 4, e441-e449.	3.9	17
89	Factor XIII Val34Leu polymorphism does not contribute to the prevention of thrombotic complications in patients with antiphospholipid syndrome. Lupus, 2004, 13, 32-35.	1.6	15
90	Osteopontin and Disease Activity in Patients with Recent-onset Systemic Lupus Erythematosus: Results from the SLICC Inception Cohort. Journal of Rheumatology, 2019, 46, 492-500.	2.0	15

#	Article	IF	CITATIONS
91	Biologic treatments in Takayasu's Arteritis: A comparative study of tumor necrosis factor inhibitors and tocilizumab. Seminars in Arthritis and Rheumatism, 2021, 51, 1224-1229.	3.4	15
92	Amyopathic Dermatomyositis Associated with Cervical Cancer. Clinical Rheumatology, 2001, 20, 438-440.	2.2	14
93	Comparing femaleâ€based contraceptive methods in patients with systemic lupus erythematosus, rheumatoid arthritis and a healthy population. International Journal of Rheumatic Diseases, 2014, 17, 653-657.	1.9	14
94	Lower vitamin D is associated with metabolic syndrome and insulin resistance in systemic lupus: data from an international inception cohort. Rheumatology, 2021, 60, 4737-4747.	1.9	14
95	Viral hepatitis screening guideline before biological drug use in rheumatic patients. European Journal of Rheumatology, 2016, 3, 25-28.	0.6	14
96	Re-evaluation of 129 patients with systemic necrotizing vasculitides by using classification algorithm according to consensus methodology. Clinical Rheumatology, 2012, 31, 325-328.	2.2	13
97	Capillaroscopic findings and vascular biomarkers in systemic sclerosis: Association of low CD40L levels with late scleroderma pattern. Microvascular Research, 2016, 108, 17-21.	2.5	13
98	Increased serum leptin levels are associated with metabolic syndrome and carotid intima media thickness in premenopausal systemic lupus erythematosus patients without clinical atherosclerotic vascular events. Lupus, 2018, 27, 1509-1516.	1.6	13
99	Cancer Risk in a Large Inception Systemic Lupus Erythematosus Cohort: Effects of Demographic Characteristics, Smoking, and Medications. Arthritis Care and Research, 2021, 73, 1789-1795.	3.4	13
100	The Use of Two Different Health Assessment Questionnaires in Turkish Rheumatoid Arthritis Population and Assessment of the Associations with Disability. Clinical Rheumatology, 1999, 18, 33-37.	2.2	12
101	Low aspirin use and high prevalence of pre-eclampsia risk factors among pregnant women in a multinational SLE inception cohort. Annals of the Rheumatic Diseases, 2019, 78, 1010-1012.	0.9	12
102	Development of hairy cell leukemia in a patient with antiphospholipid syndrome. Lupus, 2007, 16, 286-288.	1.6	10
103	Coexistence of homozygous factor V Leiden mutation and antiphospholipid antibodies in two patients presented with Budd-Chiari syndrome. Haematologia, 2002, 32, 73-77.	0.3	9
104	The Relationship between P-Selectin Polymorphisms and Thrombosis in Antiphospholipid Syndrome: A Pilot Case-Control Study. Turkish Journal of Haematology, 2014, 31, 357-362.	0.5	9
105	Prediction of hospitalizations in systemic lupus erythematosus using the Systemic Lupus International Collaborating Clinics Frailty Index (SLICCâ€FI). Arthritis Care and Research, 2020, , .	3.4	9
106	Longitudinal analysis of ANA in the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort. Annals of the Rheumatic Diseases, 2022, 81, 1143-1150.	0.9	9
107	Bilateral Acquired Brown Syndrome in Systemic Scleroderma. Journal of AAPOS, 2005, 9, 195-197.	0.3	8
108	Takayasu arteritis associated with systemic sclerosis. Modern Rheumatology, 2006, 16, 120-121.	1.8	8

#	Article	IF	CITATIONS
109	Very early 'Rheumatoid' arthritis cohorts: limited by selection. Rheumatology, 2006, 46, 185-187.	1.9	8
110	Clinical evaluation and comparison of different criteria for classification in Turkish patients with psoriatic arthritis. Rheumatology International, 2009, 29, 365-370.	3.0	8
111	MEFV gene variations in patients with systemic lupus erythematosus. Modern Rheumatology, 2014, 24, 93-96.	1.8	8
112	Use of combined hormonal contraceptives among women with systemic lupus erythematosus with and without medical contraindications to oestrogen. Rheumatology, 2019, 58, 1259-1267.	1.9	8
113	The relationship between nailfold capillaroscopic assessment and telangiectasia score with severity of peripheral vascular involvement in systemic sclerosis. Clinical and Experimental Rheumatology, 2015, 33, S92-7.	0.8	8
114	Microscopic colitis in patients with Takayasu's arteritis: a potential association between the two disease entities. Clinical Rheumatology, 2016, 35, 2495-2499.	2.2	7
115	The neurology of lupus. Journal of the Neurological Sciences, 2021, 424, 117419.	0.6	7
116	Neuropsychiatric Events in Systemic Lupus Erythematosus: Predictors of Occurrence and Resolution in a Longitudinal Analysis of an International Inception Cohort. Arthritis and Rheumatology, 2021, 73, 2293-2302.	5.6	7
117	Remarkable damage along with poor quality of life in Takayasu arteritis: cross-sectional results of a long-term followed-up multicentre cohort. Clinical and Experimental Rheumatology, 2017, 35 Suppl 103, 77-82.	0.8	7
118	Systemic necrotizing vasculitides in Turkey: a comparative analysis of 40 consecutive patients. Rheumatology International, 2005, 26, 16-20.	3.0	6
119	Recurrent anterior uveitis in Henoch Schonlein's vasculitis. Rheumatology International, 2010, 30, 1377-1379.	3.0	6
120	Validation of the adjusted global antiphospholipid syndrome score in a single centre cohort of APS patients from Turkey. Journal of Thrombosis and Thrombolysis, 2021, 51, 466-474.	2.1	6
121	A Patient with Classical Polyarteritis Nodosa Evolving into End Stage Renal Failure. Renal Failure, 2003, 25, 1037-1041.	2.1	5
122	An Unusual Overdose of Leflunomide in a Patient with Rheumatoid Arthritis. Annals of Pharmacotherapy, 2004, 38, 1320-1321.	1.9	5
123	Takayasu arteritis associated with systemic sclerosis. Modern Rheumatology, 2006, 16, 120-121.	1.8	5
124	Description of damage in different clusters of patients with antiphospholipid syndrome. Lupus, 2022, 31, 433-442.	1.6	5
125	Rosai–Dorfman disease with factor XII deficiency. Clinical Rheumatology, 2009, 28, 733-736.	2.2	4
126	Symptomatic osteonecrosis of the hip and knee in patients with systemic lupus erythematosus: Prevalence, pattern, and comparison of natural course. Lupus, 2021, 30, 1603-1608.	1.6	4

#	Article	IF	CITATIONS
127	Antiphospholipid Syndrome Presenting As Massive Pulmonary Embolism in a Patient With Sarcoidosis. Electronic Journal of General Medicine, 2005, 2, 173-176.	0.7	4
128	Direct and indirect healthcare costs of rheumatoid arthritis patients in Turkey. Clinical and Experimental Rheumatology, 2016, 34, 1033-1037.	0.8	4
129	Clinical evaluation and comparison of different criteria for classification in Turkish patients with psoriatic arthritis. Rheumatology International, 2008, 28, 959-964.	3.0	3
130	Anti-beta 2 glycoprotein I IgA in the SLICC classification criteria dataset. Lupus, 2021, 30, 096120332110142.	1.6	3
131	A single center survey study of systemic vasculitis and COVID-19 during the first months of pandemic. Turkish Journal of Medical Sciences, 2021, 51, 2243-2247.	0.9	3
132	Transforming growth factor-12 polymorphism and systemic lupus erythematosus. Journal of Rheumatology, 2002, 29, 1189-91.	2.0	3
133	Fc receptor gamma subunit polymorphisms and systemic lupus erythematosus. Journal of King Abdulaziz University, Islamic Economics, 2004, 25, 1445-8.	1.1	3
134	Long-term follow-up of 89 patients with giant cell arteritis: a retrospective observational study on disease characteristics, flares and organ damage. Rheumatology International, 2021, 41, 439-448.	3.0	2
135	A shared motif of hla-dpb1 affecting the susceptibility to pr3-anca positive granulomatosis with polyangiitis: comparative analysis of a Turkish cohort with matched healthy controls. Rheumatology International, 2021, 41, 1667-1672.	3.0	2
136	Chronic oxcarbazepine intoxication in a patient with primary antiphospholipid syndrome on maintenance haemodialysis. Journal of Clinical Pharmacy and Therapeutics, 2022, 47, 257-259.	1.5	2
137	The relationship between vascular biomarkers and disease characteristics in systemic sclerosis: elevated MCP-1 is predominantly associated with fibrotic manifestations. Clinical and Experimental Rheumatology, 2016, 34 Suppl 100, 110-114.	0.8	2
138	A Case of Takayasu Arteritis with Thrombotic Microangiopathy Secondary to Malignant Hypertension Due to Bilateral Renal Artery Stenosis. Open Access Rheumatology: Research and Reviews, 2022, Volume 14, 39-42.	1.6	2
139	Faible fréquence d'HLA-B27 chez des patients atteints de spondylarthrite ankylosante en Turquie. Revue Du Rhumatisme (Edition Francaise), 2008, 75, 433-437.	0.0	1
140	Biologics use in sle in 23 centers – data from the international registry for biologics in SLE. Annals of the Rheumatic Diseases, 2012, 71, A9.1-A9.	0.9	1
141	Reply. Arthritis Care and Research, 2016, 68, 1053-1054.	3.4	1
142	Nitrated nucleosome levels and neuropsychiatric events in systemic lupus erythematosus; a multi-center retrospective case-control study. Arthritis Research and Therapy, 2017, 19, 287.	3.5	1
143	High risk of systemic lupus erythematosus development in patients with ITP: antiphospholipid syndrome is also a concern. Annals of the Rheumatic Diseases, 2022, 81, e110-e110.	0.9	1
144	A Prodrome of Acute Lymphoblastic Leukemia Mimicking Sacroiliitis. Electronic Journal of General Medicine, 2011, 8, .	0.7	1

#	Article	IF	CITATIONS
145	The relationship between serum A proliferation-inducing ligand and B-cell activating factor levels with disease activity and organ involvement in systemic lupus erythematosus. Lupus, 2022, 31, 555-564.	1.6	1
146	Effect of Ground-Based Walk Training in Pulmonary Hypertension. American Journal of Cardiology, 2022, 174, 172-178.	1.6	1
147	Assessment Of Subclinical Cardiac Dysfunction In Diffuse Scleroderma Patients. Medical Journal of the Trakya University, 2009, , .	0.0	0
148	Comparison of ultraviolet B-induced cutaneous inflammation and skin pathergy test in Behçet's disease. International Journal of Clinical Rheumatology, 2013, 8, 205-211.	0.3	0
149	Miscellaneous inflammatory musculoskeletal conditions: Always a diagnostic and therapeutic challenge. Best Practice and Research in Clinical Rheumatology, 2016, 30, 221.	3.3	0
150	CS-07â€Economic evaluation of damage accrual in an international SLE inception cohort. , 2018, , .		0
151	FRI0392â€EVIDENCE BASED RECOMMENDATIONS FOR THE MANAGEMENT OF ENTEROPATHIC ARTHRITIS: A RHEUMATOLOGY, GASTROENTEROLOGY COLLABORATIVE INITIATIVE. , 2019, , .		0
152	SAT0184â€ASSOCIATION OF SERUM AND URINE LEVELS OF TWEAK, MCP-1 AND NGAL WITH DISEASE ACTIVIT SYSTEMIC LUPUS ERYTHEMATOSUS. , 2019, , .	'Y IN	0
153	P69â€Risk factors for adverse pregnancy outcome in patients with SLE. , 2020, , .		0
154	P73â€The relationship between pregnancy, disease activity and adverse pregnancy outcomes in systemic lupus erythematosus. , 2020, , .		0
155	P9â€Validation of the adjusted global antiphospholipid syndrome score and correlation with extra-criteria manifestations. , 2020, , .		0
156	The Prevalence and Clinical Significance of Inherited Thrombophilic Risk Factors in Patients with Antiphospholipid Syndrome Blood, 2004, 104, 4050-4050.	1.4	0
157	P-Selectin Glycoprotein Ligand-1 VNTR Polymorphisms in Systemic Sclerosis Blood, 2007, 110, 3914-3914.	1.4	0
158	Antibodies to β2-glycoprotein I in patients with systemic lupus erythematosus: Comment on the articles by Tsutsumi et al and Roubey et al. Arthritis and Rheumatism, 1997, 40, 1366-1366.	6.7	0
159	Cardiovascular risk in antiphospholipid syndrome: A comparison of thrombotic and obstetric disease subsets. Ulusal Romatoloji Dergisi, 2020, 12, 83-87.	0.0	0
160	1704â€Identifying clusters of longitudinal autoantibody profiles associated with systemic lupus erythematosus disease outcomes. , 2021, , .		0
161	Real life data of secukinumab in ankylosing spondylitis and psoriatic arthritis: Analysis of 44 patients in a single center. Ulusal Romatoloji Dergisi, 2021, 13, 116-120.	0.0	0
162	Clinical characteristics of female patients with axial spondyloarthritis treated with tumor necrosis factor-alpha inhibitors and disease related outcomes after therapy. Ulusal Romatoloji Dergisi, 2021, 13, 100-106.	0.0	0

#	Article	IF	CITATIONS
163	A Case of Budd-Chiari Syndrome Associated With Antiphospholipid Syndrome Treated Successfully by Transjugular Intrahepatic Portosystemic Shunt. Clinical Medicine Insights: Case Reports, 2022, 15, 117954762211005.	0.7	0
164	Antineutrophil Cytoplasmic Antibody-Associated Vasculitis and COVID-19. Journal of Clinical Rheumatology, 0, Publish Ahead of Print, .	0.9	0